Track your nutrition and health goals
Farxiga (Forxiga) Weight Loss: How Much, How Fast & What to Expect
By Dr. Sumedha Verma, Consultant Physician at Clearcals
Note: This article is for informational purposes only. Farxiga/Forxiga is a prescription medication. Always consult your doctor or healthcare provider before starting, stopping, or adjusting any medication.
Farxiga (dapagliflozin) is an SGLT2 inhibitor approved for type 2 diabetes, heart failure, and chronic kidney disease. In India and most markets outside the US and Canada, the same drug is sold as Forxiga by AstraZeneca — Farxiga and Forxiga are identical medications, same active ingredient (dapagliflozin), same dosing, same clinical data.
Weight loss is a well-documented side effect of dapagliflozin. This guide covers what the clinical trial data actually says about how much weight loss to expect, how quickly it occurs, and what happens when you stop.
TL;DR
- Yes, Farxiga/Forxiga causes weight loss — through urinary glucose excretion (~70g glucose/day = ~280 kcal/day)
- Average weight loss in clinical trials: 2–3 kg over 24 weeks; ~3–4% of body weight at 2 years
- How rapid: Most weight loss occurs in the first 3–6 months; it then plateaus
- Forxiga 10mg produces slightly more weight loss than 5mg
- If losing too much weight: This is uncommon but can signal volume depletion — consult your doctor
- Stopping Farxiga: Weight typically returns within weeks to months as glucose excretion stops
- Not approved for weight loss in non-diabetics as a primary indication; evidence is emerging
- Farxiga = Forxiga = dapagliflozin — same drug, different brand names by market
Farxiga vs Forxiga — Are They the Same Drug?
Yes. The distinction is purely geographic branding:
| Brand Name | Markets | Active Ingredient | Manufacturer |
|---|---|---|---|
| Farxiga | USA, Canada | Dapagliflozin | AstraZeneca |
| Forxiga | India, UK, EU, Australia, most other markets | Dapagliflozin | AstraZeneca |
The clinical trials, dosing, mechanism of action, and side effect profile are identical. When you see "forxiga weight loss" or "farxiga weight loss" searches, they refer to the same thing. Throughout this article, both names are used interchangeably.
Does Farxiga (Forxiga) Cause Weight Loss?
Yes — and the mechanism is well understood.
Dapagliflozin inhibits SGLT2 (Sodium-Glucose Cotransporter 2), a protein in the kidneys responsible for reabsorbing glucose from urine back into the bloodstream. When SGLT2 is blocked, the kidneys excrete approximately 60–90g of glucose per day through urine instead of reabsorbing it.
The calorie math:
- 70g glucose/day × 4 kcal/g = ~280 kcal excreted daily
- Over 30 days: ~8,400 kcal "lost" via urine
- Equivalent to approximately 1 kg of body fat per month — before accounting for any compensatory eating
In practice, the actual weight loss is lower than the pure calorie calculation predicts, because the body partially compensates by increasing appetite and reducing energy expenditure. This is why the real-world weight loss averages 2–3 kg rather than the theoretical ~3–4 kg over 3 months.
How Rapid Is Weight Loss with Farxiga?
This is one of the most frequently searched questions about Forxiga/Farxiga weight loss. Here is what the clinical evidence shows:
Timeline Based on Clinical Trial Data
| Timeframe | Average Weight Loss (Farxiga 10mg) |
|---|---|
| 4 weeks | 0.5–1.0 kg |
| 12 weeks | 1.5–2.0 kg |
| 24 weeks (6 months) | 2.0–3.0 kg |
| 52 weeks (1 year) | 2.5–3.5 kg |
| 2 years | 3.0–4.0 kg (approximately 3–4% body weight) |
Key sources:
- DECLARE-TIMI 58 trial (17,160 patients, 4.2 years): Patients on dapagliflozin maintained ~2 kg lower body weight versus placebo throughout the trial
- DAPA-HF trial (heart failure patients): Consistent modest weight reduction observed
- Multiple phase III diabetes trials (DURATION programme): Mean weight loss of 2.1–3.2 kg at 24 weeks for the 10mg dose
What the Weight Loss Pattern Looks Like
Weight loss is typically fastest in the first 3–6 months and then plateaus. This plateau occurs because:
- The body partially compensates with increased appetite signals
- Reduced blood glucose (less glucotoxicity) can improve insulin sensitivity, which encourages nutrient storage
- The kidneys may partially upregulate other glucose transporters over time
Most patients do not continue losing weight beyond 3–4% of body weight on Farxiga alone. For more aggressive weight loss, Farxiga/Forxiga is often combined with dietary intervention, exercise, or other medications.
Forxiga 10mg vs 5mg for Weight Loss
The 10mg dose consistently produces more weight loss than the 5mg dose:
| Dose | Typical Weight Loss at 24 Weeks |
|---|---|
| Forxiga 5mg | 1.5–2.0 kg |
| Forxiga 10mg | 2.0–3.0 kg |
The 5mg dose is the standard starting dose; 10mg is used when greater glycaemic control is needed or in patients who tolerate the 5mg dose well. Weight loss benefit is a secondary consideration — always follow your doctor's dosing recommendation.
Forxiga Weight Loss Results — What to Realistically Expect
Clinical averages don't tell the full story. Here is a realistic breakdown of outcomes:
Best responders (~20% of patients): Weight loss of 4–6 kg over the first year. These tend to be patients with higher baseline weight, who do not significantly compensate with increased eating, and who combine the medication with dietary changes.
Average responders (~60% of patients): Weight loss of 2–3 kg over 6 months, plateauing thereafter. This is the range most clinical trials report as the mean.
Minimal responders (~20% of patients): Weight loss of less than 1 kg or no meaningful change. Reasons include significant compensatory eating, other medications that promote weight gain (e.g., insulin, sulphonylureas), or individual metabolic differences.
Important: Farxiga/Forxiga is not a weight loss drug in the same class as GLP-1 agonists (Ozempic, Wegovy). The weight loss effect is modest and secondary to its primary glucose-lowering and cardiovascular/renal protective effects.
Excessive Weight Loss on Forxiga — When to Be Concerned
"Forxiga losing too much weight" is a common patient concern. Unexpectedly rapid or excessive weight loss on dapagliflozin can have two explanations:
1. Volume Depletion (More Common)
Forxiga causes osmotic diuresis — the excess glucose in urine draws water with it, increasing urine output. This can cause:
- Apparent rapid weight loss (1–3 kg) in the first 1–2 weeks, primarily from fluid loss
- Dehydration symptoms: dizziness on standing, dry mouth, reduced urine output, lightheadedness
- Electrolyte imbalance
What to do: Increase water intake (see water section below). If dizziness on standing (orthostatic hypotension) occurs, consult your doctor — dose reduction or temporary pause may be needed.
2. Euglycaemic DKA (Rare but Serious)
In very rare cases, SGLT2 inhibitors can cause euglycaemic diabetic ketoacidosis (DKA) — dangerously elevated ketones even with near-normal blood glucose. Symptoms include:
- Nausea, vomiting, abdominal pain
- Shortness of breath
- Fatigue
- Unusual thirst
If you experience these symptoms, seek emergency medical care immediately. Do not assume the weight loss is beneficial — rapid unexplained weight loss with these symptoms requires urgent evaluation.
How Much Water Should You Drink When Taking Farxiga?
This is important and frequently underemphasised in patient education.
Recommended: A minimum of 2.5–3 litres (10–12 glasses) of water per day for patients on Forxiga/Farxiga. More if you are physically active, in hot weather, or have a higher body weight.
Why it matters: Farxiga increases glucose excretion, which creates an osmotic pull that increases urine output. Without adequate hydration:
- Dehydration develops, causing headaches, dizziness, and fatigue
- Blood pressure can drop, particularly when standing (orthostatic hypotension)
- Risk of urinary tract infections increases
- Kidney function may be transiently impaired (the drug is contraindicated with eGFR below 45 ml/min/1.73m²)
Practical tips:
- Keep a water bottle visible throughout the day — passive reminders significantly improve intake
- Increase intake during summer, travel, or illness
- Signs of inadequate hydration: dark urine, reduced urine frequency, persistent dry mouth
- Use the hydration tracking feature in the Hint app to log daily intake
What Happens If You Stop Taking Farxiga?
When dapagliflozin is stopped, the SGLT2 transporters resume reabsorbing glucose normally. The calorie excretion mechanism stops, and the body typically regains the lost weight:
- Glucose re-absorption resumes within 24–48 hours of stopping
- Weight regain typically begins within 2–4 weeks
- Most of the lost weight returns within 2–4 months in most patients
- Blood sugar returns to pre-treatment levels without other interventions
This is similar to the rebound seen with GLP-1 agonists when stopped — the medication manages a chronic condition; it does not cure the underlying metabolic drivers.
Stopping before surgery: Farxiga/Forxiga should be paused 3 days before any surgical procedure due to risk of perioperative euglycaemic DKA. Always inform your surgical team and anaesthetist that you are on an SGLT2 inhibitor.
Stopping suddenly: Unlike some medications, dapagliflozin does not require gradual tapering — it can be stopped abruptly. However, blood sugar monitoring should be increased after stopping, as glucose control will deteriorate.
Farxiga (Forxiga) for Weight Loss in Non-Diabetics
This is an emerging area of research. Farxiga/Forxiga is not currently approved for weight loss as a standalone indication in non-diabetics, but the evidence is accumulating:
- The DAPA-CKD and DAPA-HF trials included many patients without type 2 diabetes — the drug showed consistent benefits for heart failure and kidney protection, with modest weight loss in these populations
- Farxiga received FDA approval in 2021 for chronic kidney disease regardless of diabetes status, and for heart failure with reduced ejection fraction — demonstrating benefit beyond pure glucose management
- Studies in obesity without diabetes show modest but consistent weight loss (~2 kg over 24 weeks)
Currently, if weight loss is the primary goal in a non-diabetic patient, GLP-1 agonists (semaglutide/Ozempic, tirzepatide/Mounjaro) produce substantially greater weight loss (10–15% vs 2–4%). Farxiga's role in non-diabetic weight management remains complementary rather than primary.
Farxiga and Metformin for Weight Loss
Farxiga is frequently prescribed with Metformin in type 2 diabetes. Their mechanisms complement each other:
| Drug | Primary Mechanism | Weight Effect |
|---|---|---|
| Metformin | Reduces hepatic glucose production; improves insulin sensitivity | Modest weight loss or weight neutral (~1–2 kg) |
| Farxiga/Forxiga | Increases urinary glucose excretion | Modest weight loss (~2–3 kg) |
| Combination | Both mechanisms active | Additive effect — ~3–5 kg combined |
The combination does not cause hypoglycaemia (neither drug by itself causes low blood sugar in most patients), making it generally safe from a glucose management perspective.
Farxiga vs Jardiance for Weight Loss
Both are SGLT2 inhibitors. The weight loss data is similar:
| Farxiga / Forxiga (dapagliflozin) | Jardiance (empagliflozin) | |
|---|---|---|
| Average weight loss | 2–3 kg at 24 weeks | 2–3 kg at 24 weeks |
| Mechanism | SGLT2 inhibition | SGLT2 inhibition |
| Cardiovascular evidence | DECLARE-TIMI 58 — reduced HHF/CV death | EMPA-REG OUTCOME — reduced CV mortality |
| Kidney evidence | DAPA-CKD — strong CKD benefit | EMPA-KIDNEY — strong CKD benefit |
| Available in India as | Forxiga | Jardiance |
| Generic available | Dapagliflozin (available in India) | Empagliflozin |
For weight loss specifically, there is no meaningful clinical difference. Choice between the two is usually driven by cardiovascular/renal risk profile, tolerability, availability, and cost — not by weight loss magnitude.
Farxiga vs Ozempic for Weight Loss
These are fundamentally different classes with very different weight loss magnitudes:
| Farxiga / Forxiga (dapagliflozin) | Ozempic (semaglutide) | |
|---|---|---|
| Drug class | SGLT2 inhibitor | GLP-1 receptor agonist |
| Mechanism | Urinary glucose excretion | Appetite suppression + slowed gastric emptying |
| Average weight loss | 2–4% body weight (~2–3 kg) | 10–15% body weight (~12–15 kg) |
| Administration | Once-daily oral tablet | Once-weekly subcutaneous injection |
| Primary indication | T2DM, heart failure, CKD | T2DM; weight management (Wegovy formulation) |
| Side effects | UTI, genital infection, polyuria, DKA (rare) | Nausea, vomiting, GI discomfort (common initially) |
| Cost in India | Forxiga 10mg ~₹1,800–2,500/month; generic dapagliflozin available | Ozempic ~₹6,000–10,000+/month |
For patients primarily seeking weight loss, Ozempic-class drugs (GLP-1 agonists) produce substantially greater results. However, Farxiga/Forxiga has advantages in cardiac and renal protection that Ozempic does not replicate at the same evidence level. Many patients are prescribed both for synergistic metabolic and cardiovascular benefit.
For more detail, see our article: Ozempic for Weight Loss
Farxiga Side Effects Related to Weight
Common Side Effects That May Affect Weight and Wellbeing
| Side Effect | Frequency | Weight Relevance |
|---|---|---|
| Increased urination | Very common | Contributes to initial "water weight" loss |
| Genital yeast infection | Common (women > men) | Not directly weight-related but discomforting |
| Urinary tract infection | Common | Not directly weight-related |
| Dehydration / thirst | Common | Apparent weight loss from fluid; requires hydration |
| Nausea | Uncommon | Can reduce appetite initially |
| Volume depletion / dizziness | Uncommon | Rapid apparent weight loss — see excessive weight loss section |
| DKA | Rare | Serious; requires immediate attention |
| Fournier's gangrene | Very rare | Serious urogenital infection |
Farxiga Side Effects in Elderly Patients
Older patients (>65 years) are at higher risk for volume depletion and associated dizziness/falls. Water intake guidance is especially important. Blood pressure medications may need adjustment when Farxiga is added, as the combined blood pressure lowering effect can be significant.
Farxiga Dosage for Weight Loss
| Indication | Starting Dose | Maximum Dose |
|---|---|---|
| Type 2 diabetes | 5 mg once daily | 10 mg once daily |
| Heart failure | 10 mg once daily | 10 mg once daily |
| Chronic kidney disease | 10 mg once daily | 10 mg once daily |
Can you take 20mg? No — 10mg is the maximum approved dose. Higher doses do not increase glucose excretion proportionally and increase the risk of side effects without added benefit.
Best time to take Farxiga: Farxiga/Forxiga can be taken with or without food. There is no strong clinical evidence favoring morning over evening. Most patients take it in the morning to avoid increased nighttime urination, but if you experience dizziness in the morning (from blood pressure effects), evening dosing may be better — discuss with your doctor.
Foods to avoid when taking Farxiga:
- Excessive sugar and refined carbohydrates: These increase blood glucose and the glucose load on the kidneys, amplifying side effects
- Alcohol: Increases risk of dehydration and hypoglycaemia (especially if also on insulin or sulphonylureas)
- Very low-carbohydrate diets (keto): Significantly increase risk of euglycaemic DKA on SGLT2 inhibitors — consult your doctor before combining Farxiga with a ketogenic diet
Drug Interactions
Certain medications can interact with Farxiga:
- Diuretics (furosemide, hydrochlorothiazide): Additive effect on fluid/electrolyte loss — higher dehydration risk
- Insulin and sulphonylureas: Increased hypoglycaemia risk when combined — dose reduction of insulin/sulphonylurea often needed
- Other SGLT2 inhibitors: Not to be combined
- NSAIDs: Can impair kidney function — avoid prolonged use while on Farxiga
Is There a Generic Version of Farxiga Available in India?
Yes. The generic form of dapagliflozin is available in India under multiple brand names at significantly lower cost:
- Forxiga 10mg (AstraZeneca branded): ~₹1,800–2,500/month (30 tablets)
- Generic dapagliflozin 10mg: ~₹400–800/month depending on brand
Common Indian generics include Dapaglyn, Forxiga (biosimilar), and several others. Ask your pharmacist or doctor for the generic equivalent — it is the same active molecule at the same dose.
Supporting Your Farxiga Weight Loss with Diet and Tracking
Farxiga/Forxiga's modest weight loss effect is best amplified by concurrent dietary intervention. The drug excretes ~280 kcal/day through urine — a dietary deficit of a further 200–300 kcal/day through portion control can double the effective calorie deficit without requiring dramatic dietary changes.
The Hint app supports Farxiga users specifically through:
- Calorie and macro tracking: Understand the dietary side of your weight loss alongside the pharmacological effect
- Water intake tracking: Critical for Farxiga users — the app's hydration reminders and logging help maintain the recommended 2.5–3L/day
- Blood sugar-friendly food database: Indian foods with glycaemic index data — useful for choosing foods that complement Farxiga's glucose-lowering effect
- Progress tracking: Monitor weight loss trends over the months-long timeline relevant to SGLT2 inhibitor treatment
Hint Premium includes unlimited dietitian consultations — our dietitians can create personalised meal plans that maximise weight loss alongside your Farxiga/Forxiga regimen.
Frequently Asked Questions
Is Farxiga and Forxiga the same drug?
Yes. Farxiga (US/Canada) and Forxiga (India, UK, EU, Australia) are the same drug — dapagliflozin 10mg made by AstraZeneca. The clinical data, dosing, and side effects are identical.
Does Farxiga cause weight loss?
Yes. By excreting approximately 70g of glucose per day through urine (~280 kcal/day), Farxiga/Forxiga produces a modest but consistent weight loss of 2–3 kg on average over 24 weeks in clinical trials.
How rapid is weight loss with Farxiga?
Most weight loss occurs in the first 3–6 months. Typical progression: ~1 kg by 4 weeks, ~2 kg by 12 weeks, 2–3 kg by 6 months. Weight then plateaus. It is not rapid weight loss — GLP-1 agonists like Ozempic produce 4–5× more weight loss.
Can Forxiga cause too much weight loss?
Very rapid early weight loss (first 1–2 weeks) is usually fluid loss from osmotic diuresis, not fat. If accompanied by dizziness, dry mouth, or low blood pressure on standing, this signals volume depletion — increase water intake and consult your doctor. Genuine excessive fat loss on Farxiga alone is uncommon.
Will I gain weight back if I stop taking Farxiga?
Yes — in most patients, weight returns within 2–4 months of stopping as glucose excretion ceases and the caloric deficit disappears.
Can a non-diabetic take Farxiga for weight loss?
Farxiga is approved for non-diabetic patients with heart failure or chronic kidney disease, but not specifically for weight loss. Off-label use for obesity in non-diabetics does occur and shows modest benefit, but GLP-1 agonists are the preferred agents for primary weight loss in non-diabetics.
What is the best time to take Farxiga for weight loss?
There is no clinical difference in weight loss outcomes based on timing. Morning dosing is preferred by most patients to avoid nighttime urination, but evening dosing may be better if morning blood pressure dips cause dizziness.
How much water should I drink on Forxiga?
Aim for 2.5–3 litres (10–12 glasses) of water daily. Increase this in hot weather, during exercise, or during illness. Dark urine, dry mouth, and dizziness on standing are signs of inadequate hydration.
Is Farxiga better than Jardiance for weight loss?
Both produce similar weight loss (~2–3 kg). The choice between them is driven by cardiovascular risk profile, kidney function, cost, and availability rather than weight loss difference.
References
- Wiviott SD, et al. (2019). Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. NEJM, 380:347–357. DOI: 10.1056/NEJMoa1812389 (DECLARE-TIMI 58)
- McMurray JJV, et al. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. NEJM, 381:1995–2008. DOI: 10.1056/NEJMoa1911303 (DAPA-HF)
- Heerspink HJL, et al. (2020). Dapagliflozin in Patients with Chronic Kidney Disease. NEJM, 383:1436–1446. DOI: 10.1056/NEJMoa2024816 (DAPA-CKD)
- Bolinder J, et al. (2012). Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes. J Clin Endocrinol Metab, 97(3):1020–31. DOI: 10.1210/jc.2011-2260
- Ferrannini E, et al. (2012). Metabolic response to sodium-glucose cotransporter 2 inhibition. J Clin Invest, 122(12):4625–4631. DOI: 10.1172/JCI65041
🎁 Exclusive Offer for Clearcals Store Customers
- Buy select Garmin watches → Get 1 Month FREE Hint Premium (worth ₹1,999)
- Buy Apple Watch models → Get FREE Hint Pro access
Explore More
About the Author
Dr. Sumedha Verma is a Consultant Physician at Clearcals with extensive experience in clinical medicine and healthcare services.
She has significant expertise in managing metabolic conditions such as fatty liver, diabetes, thyroid disorders, PCOS, infertility, and other gynecological health concerns.
Known for her patient-centered approach, Dr. Verma focuses on improving patient compliance and helping individuals achieve better health outcomes through personalized medical guidance and long-term care.
🔗 Connect with Dr. Sumedha on LinkedIn
